Detalhe da pesquisa
1.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35115180
2.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.
Lancet Oncol
; 22(5): 632-642, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862001
3.
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(12): 1721-1731, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715071
4.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(5): 620-631, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743851
5.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
N Engl J Med
; 379(26): 2495-2505, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345884
6.
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.
Gynecol Oncol
; 163(1): 41-49, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34353615
7.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
Br J Cancer
; 119(9): 1075-1085, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353045
8.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(9): 1274-1284, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28754483
9.
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Lancet Oncol
; 16(1): 87-97, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25481791
10.
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 15(5): R88, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24063698
11.
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
J Clin Oncol
; 41(3): 609-617, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36082969
12.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Breast Cancer Res Treat
; 133(1): 237-46, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22286314
13.
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Clin Cancer Res
; 28(19): 4186-4193, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917514
14.
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
J Clin Oncol
; 38(11): 1164-1174, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32073956
15.
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
J Clin Oncol
; 38(30): 3528-3537, 2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749942
16.
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Lancet
; 372(9652): 1809-18, 2008 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19027483
17.
The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome.
J Clin Endocrinol Metab
; 93(7): 2751-4, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18397987
18.
Reply to S. Gulia et al.
J Clin Oncol
; 39(3): 256, 2021 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33326256
19.
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Head Neck
; 38(3): 439-47, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25352401
20.
Reply to E. Paulino et al.
J Clin Oncol
; 38(23): 2698, 2020 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32530766